Kanada - Ingliż - Health Canada

apotex inc - deferasirox - tablet - 360mg - deferasirox 360mg - heavy metal antagonists

Kanada - Ingliż - Health Canada

taro pharmaceuticals inc - deferasirox - tablet - 90mg - deferasirox 90mg - heavy metal antagonists

Kanada - Ingliż - Health Canada

taro pharmaceuticals inc - deferasirox - tablet - 180mg - deferasirox 180mg - heavy metal antagonists

Kanada - Ingliż - Health Canada

taro pharmaceuticals inc - deferasirox - tablet - 360mg - deferasirox 360mg - heavy metal antagonists

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: poloxamer; purified talc; titanium dioxide; indigo carmine aluminium lake; hypromellose; magnesium stearate; colloidal anhydrous silica; povidone; macrogol 4000; microcrystalline cellulose; crospovidone - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox-teva is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox-teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: magnesium stearate; titanium dioxide; hypromellose; purified talc; microcrystalline cellulose; povidone; poloxamer; macrogol 4000; colloidal anhydrous silica; crospovidone; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older.deferasirox-teva is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox-teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: purified talc; poloxamer; povidone; macrogol 4000; colloidal anhydrous silica; titanium dioxide; microcrystalline cellulose; hypromellose; crospovidone; magnesium stearate; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox-teva is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox-teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older

Kanada - Ingliż - Health Canada

auro pharma inc - deferasirox - tablet - 90mg - deferasirox 90mg

Kanada - Ingliż - Health Canada

auro pharma inc - deferasirox - tablet - 180mg - deferasirox 180mg

Kanada - Ingliż - Health Canada

auro pharma inc - deferasirox - tablet - 360mg - deferasirox 360mg